ArticleJournal of nanobiotechnology2026
Cationic hydrogel with sustained lubrication and anti-calcification for osteoarthritis therapy.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundOsteoarthritis is characterized by cartilage degradation and abnormal subchondral bone remodeling, primarily due to disrupted lubrication-calcification coupling. Current treatments mainly relieve symptoms but lack effective strategies against calcification, and lubrication supplements offer only temporary relief. Here, we present a novel dual-functional cationic hydrogel designed to simultaneously enhance lubrication and inhibit pathological calcification, targeting the dysregulated lubrication-calcification interaction in OA. This approach offers a promising disease-modifying strategy for OA treatment.
resultsFormulated from alkylated modified chitosan (mCS) and lysine (Lys), the mCS/Lys hydrogel exhibits dual functionalities: inhibiting pathological calcification and enhancing joint lubrication. These effects are achieved through structural modifications that create a brush-like architecture, recruiting endogenous lubricating factors and calcification precursors due to its intrinsic surface activity. Compared to clinically utilized hyaluronic acid, mCS/Lys hydrogel demonstrates an extended duration of action and enhanced therapeutic efficacy. The intra-articular delivery of the hydrogel in a murine osteoarthritis model demonstrated that the mCS/Lys hydrogel effectively inhibits pathological calcification, alleviates pain, and promotes the repair of articular cartilage.
conclusionsOverall, the mCS/Lys hydrogel offers a more holistic and enduring treatment approach by integrating sustained lubrication with anti-calcification features. Compared to traditional single-target methods, it indicates a promising, translatable solution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.